Cargando…
Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2
The aim of this study was to investigate the effectiveness of SGLT2 inhibitors with regard to metabolic parameters and patient safety under routine ambulatory conditions. Retrospective longitudinal study of 95 patients with type 2 diabetes (diabetes duration 13.3 y; HbA1c 8.9%; eGFR 80.1 mL/min) rec...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913515/ https://www.ncbi.nlm.nih.gov/pubmed/33546360 http://dx.doi.org/10.3390/jcm10040571 |
_version_ | 1783656819893207040 |
---|---|
author | Hopf, Maximilian Kloos, Christof Wolf, Gunter Müller, Ulrich Alfons Müller, Nicolle |
author_facet | Hopf, Maximilian Kloos, Christof Wolf, Gunter Müller, Ulrich Alfons Müller, Nicolle |
author_sort | Hopf, Maximilian |
collection | PubMed |
description | The aim of this study was to investigate the effectiveness of SGLT2 inhibitors with regard to metabolic parameters and patient safety under routine ambulatory conditions. Retrospective longitudinal study of 95 patients with type 2 diabetes (diabetes duration 13.3 y; HbA1c 8.9%; eGFR 80.1 mL/min) receiving SGLT-2-inhibitors. Metabolic control and adverse event profile were evaluated. The mean follow-up time was 1.2 ± 0.8 years. The following changes were observed: HbA1c −1.0% ± 1.9 (p < 0.001), eGFR −7.0 mL/min ± 13.3 (p < 0.001), albuminuria −23.9 mg/g creatinine ± 144.5 (p = 0.118), bodyweight −3.0 kg ± 5.8 (p < 0.001), systolic blood pressure −6 mmHg ± 22 (p = 0.01), diastolic blood pressure −2 mmHg ± 14 (p = 0.243). 53 participants continuously applied the therapy. Twenty-eight participants discontinued SGLT-2-inhibitors due to various reasons: 20 participants because of genital- or urinary tract infections. One for dysuria, seven due to reduced eGFR below 45 mL/min. This study showed a considerable reduction of HbA1c and a modest reduction of eGFR, bodyweight and systolic blood pressure under clinical routine conditions. Genital infections occurred markedly more often than in randomized controlled trials. To apply SGLT-2-inhibitors more safely in clinical routine individual risks for genital and urinary tract infections should be considered and re-evaluated during therapy. |
format | Online Article Text |
id | pubmed-7913515 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79135152021-02-28 Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2 Hopf, Maximilian Kloos, Christof Wolf, Gunter Müller, Ulrich Alfons Müller, Nicolle J Clin Med Article The aim of this study was to investigate the effectiveness of SGLT2 inhibitors with regard to metabolic parameters and patient safety under routine ambulatory conditions. Retrospective longitudinal study of 95 patients with type 2 diabetes (diabetes duration 13.3 y; HbA1c 8.9%; eGFR 80.1 mL/min) receiving SGLT-2-inhibitors. Metabolic control and adverse event profile were evaluated. The mean follow-up time was 1.2 ± 0.8 years. The following changes were observed: HbA1c −1.0% ± 1.9 (p < 0.001), eGFR −7.0 mL/min ± 13.3 (p < 0.001), albuminuria −23.9 mg/g creatinine ± 144.5 (p = 0.118), bodyweight −3.0 kg ± 5.8 (p < 0.001), systolic blood pressure −6 mmHg ± 22 (p = 0.01), diastolic blood pressure −2 mmHg ± 14 (p = 0.243). 53 participants continuously applied the therapy. Twenty-eight participants discontinued SGLT-2-inhibitors due to various reasons: 20 participants because of genital- or urinary tract infections. One for dysuria, seven due to reduced eGFR below 45 mL/min. This study showed a considerable reduction of HbA1c and a modest reduction of eGFR, bodyweight and systolic blood pressure under clinical routine conditions. Genital infections occurred markedly more often than in randomized controlled trials. To apply SGLT-2-inhibitors more safely in clinical routine individual risks for genital and urinary tract infections should be considered and re-evaluated during therapy. MDPI 2021-02-03 /pmc/articles/PMC7913515/ /pubmed/33546360 http://dx.doi.org/10.3390/jcm10040571 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hopf, Maximilian Kloos, Christof Wolf, Gunter Müller, Ulrich Alfons Müller, Nicolle Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2 |
title | Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2 |
title_full | Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2 |
title_fullStr | Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2 |
title_full_unstemmed | Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2 |
title_short | Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2 |
title_sort | effectiveness and safety of sglt2 inhibitors in clinical routine treatment of patients with diabetes mellitus type 2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913515/ https://www.ncbi.nlm.nih.gov/pubmed/33546360 http://dx.doi.org/10.3390/jcm10040571 |
work_keys_str_mv | AT hopfmaximilian effectivenessandsafetyofsglt2inhibitorsinclinicalroutinetreatmentofpatientswithdiabetesmellitustype2 AT klooschristof effectivenessandsafetyofsglt2inhibitorsinclinicalroutinetreatmentofpatientswithdiabetesmellitustype2 AT wolfgunter effectivenessandsafetyofsglt2inhibitorsinclinicalroutinetreatmentofpatientswithdiabetesmellitustype2 AT mullerulrichalfons effectivenessandsafetyofsglt2inhibitorsinclinicalroutinetreatmentofpatientswithdiabetesmellitustype2 AT mullernicolle effectivenessandsafetyofsglt2inhibitorsinclinicalroutinetreatmentofpatientswithdiabetesmellitustype2 |